Table 1.
Cancer types in which an upregulated gene expression is correlated with the FDA-approved drug for that cancer
| Cancer | Targeted protein: current FDA-approved antineoplastic drug(s) |
|---|---|
| Glioblastoma | VEGF: bevacizumab |
| Breast cancer (two groups) | ERBB2: trastuzumab |
| Colorectal cancer (four groups) | VEGF: bevacizumab, EGFR: cetuximab |
| Pediatric AML | CD33: gemtuzumab |
| Chronic myeloid leukemia | ABL1: imatinib |
| Multiple myeloma (three groups) | PSMC (3, 5): bortezomib |
| Soft tissue sarcoma | KIT, PDGFR (A, B): pazopanib |
| Gastrointestinal stromal tumor | KIT, PDGFRB: imatinib |
| Hepatocellular carcinoma (four groups) | PDGFR (A, B), RAF1, BRAF, RET, KIT: sorafenib |
| Lung adenocarcinoma | EGFR: erlotinib, gefitinib, VEGF: bevacizumab |
| Lung non-small-cell cancer | EGFR: erlotinib, gefitinib |
| Renal clear cell cancer (2 groups) | VEGF: bevacizumab, RET, PDGFR (A, B), VEGFR: sorafenib, sunitinib, MTOR: everolimus |
| Renal oncocytoma cell cancer | KIT, VEGFR: sorafenib, VEGF: bevacizumab |
| Basal-like breast cancer | TOP2A: doxorubicin |
| BRCA1-mutated breast cancer (two groups) | TOP2A: doxorubicin |
| Exing sarcoma | TOP2A: doxorubicin |
| Thyroid anaplastic cancer | TOP2A: doxorubicin |
| Thyroid papillary cancer | TOP2A: doxorubicin |
| Squamous cell lung cancer (two groups) | EGFR: cetuximab |
| Fallopian serous carcinoma | TOP2A: liposomal doxorubicin |
| Clear cell ovarian cancer | TOP2A: liposomal doxorubicin |
Note: numbers within parentheses are gene members.
Abbreviations: AML, acute myeloid leukemia; FDA, US Food and Drug Administration; BRCAI, breast cancer I gene.